Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled date : 2021 - 11 - 11 save search
Eisai Presents New Analysis Of Lecanemab Clinical Efficacy Results From Phase 2b Study At Clinical Trials On Alzheimer's Disease (CTAD) Conference
Published: 2021-11-11 (Crawled : 20:00) - biospace.com/
BIIB | $190.52 -0.85% -0.84% 1.3M
|
Health Technology
|
| O: -0.12%
H: 0.37%
C: -0.02%
disease alzheimer ema phase 2 clinical trials results trials phase 2b trial conference alzheimer’s alzheimer's disease alzheimer's lecanemab
Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders
Published: 2021-11-11 (Crawled : 12:15) - prnewswire.com
ALKS | $23.76 -1.04% -0.97% 1.4M
|
Health Technology
|
| O: -1.59%
H: 1.86%
C: -1.05%
treatment neurodegenerative neurological phase 1 phase 2
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint
Published: 2021-11-11 (Crawled : 01:00) - prnewswire.com
GILD | News | $66.16 -1.15% -1.16% 4.9M
|
Health Technology
|
| O: 0.8%
H: 0.73%
C: 0.64%
phase 2 china cancer phase 2b breast cancer
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.